The Calcium Channel Blocker Bepridil Demonstrates Efficacy in the Murine Model of Marburg Virus Disease

被引：19

作者：

DeWald, Lisa Evans ^{[1
,3
]}

Dyall, Julie ^{[1
]}

Sword, Jennifer M. ^{[1
]}

Torzewski, Lisa ^{[1
]}

Zhou, Huanying ^{[1
]}

Postnikova, Elena ^{[1
]}

Kollins, Erin ^{[1
]}

Alexander, Isis ^{[1
]}

Gross, Robin ^{[1
]}

Cong, Yu ^{[1
]}

Gerhardt, Dawn M. ^{[1
]}

Johnson, Reed F. ^{[2
]}

Olinger, Gene G., Jr. ^{[1
,4
]}

Holbrook, Michael R. ^{[1
]}

Hensley, Lisa E. ^{[1
]}

Jahrling, Peter B. ^{[1
,2
]}

机构：

[1] NIAID, Integrated Res Facil, NIH, B-8200 Res Plaza, Frederick, MD 21702 USA

[2] NIAID, Emerging Viral Pathogens Sect, NIH, Frederick, MD USA

[3] Emergent BioSolut Inc, Gaithersburg, MD USA

[4] MRIGlobal Global Hlth Surveillance & Diagnost, Gaithersburg, MD USA

来源：

JOURNAL OF INFECTIOUS DISEASES | 2018年 / 218卷

关键词：

antiviral; bepridil; Marburg virus; GLYCOPROTEIN; AMIODARONE; TARGET; EBOLA;

D O I：

10.1093/infdis/jiy332

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

No therapeutics are approved for the treatment of filovirus infections. Bepridil, a calcium channel blocker developed for treating angina, was identified as a potent inhibitor of filoviruses in vitro, including Ebola and Marburg viruses, and Ebola virus in vivo. We evaluated the efficacy of bepridil in a lethal mouse model of Marburg virus disease. A dose of 12 mg/kg bepridil once or twice daily resulted in 80% or 90% survival, respectively. These data confirm bepridil's broad-spectrum anti-filovirus activity warranting further investigation of bepridil, or improved compounds with a similar mechanism, as a pan-filovirus therapeutic agent.

引用

页码：S588 / S591

页数：4

共 50 条

[1] THE BINDING OF THE CALCIUM-CHANNEL BLOCKER, BEPRIDIL, TO CALMODULIN
ITOH, H
TANAKA, T
MITANI, Y
HIDAKA, H
BIOCHEMICAL PHARMACOLOGY, 1986, 35 (02) : 217 - 220
[2] BINDING OF BEPRIDIL, A CALCIUM-CHANNEL BLOCKER, TO CALMODULIN
ITOH, H
ISHIKAWA, T
HIDAKA, H
JAPANESE CIRCULATION JOURNAL-ENGLISH EDITION, 1985, 49 (08): : 900 - 900
[3] Suppression of Metastatic Ovarian Cancer Cells by Bepridil, a Calcium Channel Blocker
Zhang, Songzi
Kim, Dokyeong
Park, Minyoung
Yin, Jing Hu
Park, Junseong
Chung, Yeun-Jun
LIFE-BASEL, 2023, 13 (07):
[4] A new and efficient enantioselective synthesis of both enantiomers of the calcium channel blocker bepridil
Mujahid, Mohammad
Subramanian, Jambu
Nalla, Viswanadh
Sasikumar, Murugesan
Kunte, Sunita Sharad
Muthukrishnan, Murugan
NEW JOURNAL OF CHEMISTRY, 2017, 41 (02) : 824 - 829
[5] CALCIUM-CHANNEL BLOCKER BEPRIDIL COMPARED TO PROPRANOLOL IN THE TREATMENT OF PATIENTS WITH CHRONIC STABLE ANGINA
DEEDWANIA, P
CARBAJAL, E
BOBBA, V
LINN, L
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 41 (02) : 241 - 241
[6] BEPRIDIL - ELECTROPHYSIOLOGIC AND ARRHYTHMOGENIC PROFILE OF A NEW CALCIUM-CHANNEL BLOCKER USED IN THE TREATMENT OF HYPERTENSION
GEIBEL, A
ZEHENDER, M
HOHNLOSER, S
MEINERTZ, T
JUST, H
HYPERTENSION, 1989, 13 (05) : 536 - 536
[7] Efficacy of Methylene Blue in an Experimental Model of Calcium Channel Blocker-Induced Shock
Jang, David H.
Donovan, Sean
Nelson, Lewis S.
Bania, Theodore C.
Hoffman, Robert S.
Chu, Jason
ANNALS OF EMERGENCY MEDICINE, 2015, 65 (04) : 410 - 415
[8] A Recombinant Rabies Virus Expressing the Marburg Virus Glycoprotein Is Dependent upon Antibody-Mediated Cellular Cytotoxicity for Protection against Marburg Virus Disease in a Murine Model
Kesbwara, Rohan
Hagen, Katie R.
Abreu-Mota, Tiago
Papaneri, Amy B.
Liu, David
Wirblich, Christoph
Johnson, Reed F.
Schnell, Matthias J.
JOURNAL OF VIROLOGY, 2019, 93 (06)
[9] Calcium channel blocker in patients with chronic kidney disease
Ohno, Shoko
Ishii, Akira
Yanagita, Motoko
Yokoi, Hideki
CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2022, 26 (03) : 207 - 215
[10] Calcium channel blocker in patients with chronic kidney disease
Shoko Ohno
Akira Ishii
Motoko Yanagita
Hideki Yokoi
Clinical and Experimental Nephrology, 2022, 26 : 207 - 215

← 1 2 3 4 5 →